X0306 4 2020-11-03 0 0001593899 Atea Pharmaceuticals, Inc. AVIR 0001657434 Hack Andrew A. F. C/O BAIN CAPITAL LIFE SCIENCES INVESTORS, 200 CLARENDON STREET BOSTON MA 02116 1 0 0 0 Common Stock 2020-11-03 4 C 0 5365659 A 5365659 I See Footnotes Common Stock 2020-11-03 4 P 0 250000 24.00 A 5615659 I See Footnotes Series D Convertible Preferred Stock 2020-11-03 4 C 0 3383190 D Common Stock 3383190 0 I See Footnotes Series D-1 Convertible Preferred Stock 2020-11-03 4 C 0 1982469 D Common Stock 1982469 0 I See Footnotes Represents shares held directly by Bain Capital Life Sciences Fund II, L.P. ("BCLS II"), BCLS II Investco, LP ("BCLS II Investco") and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS II and BCLS II Investco, the "Bain Capital Life Sciences Entities"). Bain Capital Life Sciences Investors, LLC ("BCLSI") (i) is the ultimate general partner of each of BCLS II and BCLS II Investco, and (ii) governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Managing Director of BCLSI. By virtue of the relationships described in this footnote, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock. On November 3, 2020, BCLS II Investco purchased 250,000 shares of common stock of the Issuer at a price of $24.00 per share, pursuant to an underwritten public offering. /s/ Andrew A.F. Hack 2020-11-03